Molecular and immunohistochemical evidence for the origin of uterine leiomyosarcomas from associated leiomyoma and symplastic leiomyoma-like areas

Modern Pathology

Volumn 22, Issue 10, 2009, Pages 1303-1311

  Mittal, Khush R ^a   Chen, Fan ^a   Wei, Jian J ^a   Rijhvani, Kiran ^a   Kurvathi, Rohini ^b   Streck, Deanna ^b   Dermody, James ^b   Toruner, Gokce A ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Leiomyosarcoma; Symplastic leiomyoma; Uterus

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53;

ARTICLE; CHROMOSOME; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE ASSOCIATION; DNA MICROARRAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; LEIOMYOSARCOMA; PRIORITY JOURNAL; UTERUS CANCER;

CELL TRANSFORMATION, NEOPLASTIC; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LEIOMYOMA; LEIOMYOSARCOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRECANCEROUS CONDITIONS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UTERINE NEOPLASMS;

EID: 70349659679     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.96     Document Type: Article

References (37)

1. Jones MW, Norris HJ. Clinicopathologic study of 28 uterine leiomyosarcomas with metastasis. Int J Gynecol Pathol 1995;14:243-249.
2. Wilkinson N, Rollason TP. Recent advances in the pathology of smooth muscle tumours of the uterus. Histopathology 2001;39:331-341.
3. Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early-stage uterine sarcoma: a Gynecologic Oncology Group study. Cancer 1993;71:1702-1709.
4. Oliva E, Clement PB, Young RH. Mesenchymal tumours of the uterus: selected topics emphasizing diagnostic pitfalls. Curr Diagn Pathol 2002;8:268-282.
5. Hendrickson MR, Kempson RL. A diagnostic approach to smooth muscle tumours of the uterus. Curr Diagn Pathol 2000;6:21-30.
6. Clement PB, Young RH. Mesenchymal and mixed epithelial-mesenchymal tumors of the uterine corpus and cervix. In: Clement PB (eds) Atlas of Gynecologic Surgical Pathology. WB Saunders: Philadelphia, Pa, 2000, pp 177-210.
7. Longacre TA, Hendrickson MR, Kempson RL. Predicting clinical outcome for uterine smooth muscle neoplasms with a reasonable degree of certainty. Adv Anat Pathol 1997;4:95-104.
8. Mittal K, Popiolek D, Demopoulos RI. Uterine myxoid leiomyosarcoma within a leiomyoma. Hum Pathol 2000;31:398-400.
9. Mittal K, Joutovsky A. Areas with benign morphologic and immunohistochemical features are associated with some uterine leiomyosarcomas. Gynecol Oncol 2007;104:362-365.
10. Toruner GA, Streck DL, Dermody JJ, et al. An oligonucleotide based array-CGH system for detection of genome wide copy number changes including subtelomeric regions for genetic evaluation of mental retardation. Am J Med Genet 2007;143:824-829.
11. Jatoi N. Leiomyosarcoma: rare malignant change in a leiomyoma. J Coll Physicians Surg Pak 2003; 13:106-107.
12. Kir G, Eren S, Akoz I, et al. Leiomyosarcoma of the broad ligament arising in a pre-existing pure neurilemmoma- like leiomyoma. Eur J Gynaecol Oncol 2003;24:505-506.
13. Scurry J, Hack M. Leiomyosarcoma arising in a lipoleiomyoma. Gynecol Oncol 1990;39:381-383.
14. Mittal K, Demopoulos RI. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors. Hum Pathol 2001; 32:984-987.
15. Bohmann D, Bos TJ, Admon A, et al. Human protooncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1. Science 1988;238:1386-1392.
16. Wang XC, Tian J, Tian LL, et al. Role of Cks1 amplification and overexpression in breast cancer. Biochem Biophys Res Commun 2009; 379:1107-1113.
17. Semba K, Nishizawa M, Miyajima N, et al. Yes-related protooncogene, syn, belongs to the protein-tyrosine kinase family. Proc Natl Acad Sci USA 1986;83: 5459-5463.
18. Almoguera C, Shibata D, Forrester K, et al. Most human arcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549-554.
19. Tam IY, Chung LP, Suen WS, et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res 2006;12:1647-1653.
20. Sharrocks AD, Brown AL, Ling Y, et al. The ETSdomain transcription factor family. Int J Biochem Cell Biol 1997;29:1371-1387.
21. Ohta S, Uemura H, Matsui Y, et al. Alterations of p16 and p14ARF genes and their 9p21 locus in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;107:81-91.
22. Wong VC, Chan PL, Bernabeu C, et al. Identification of an invasion and tumor-suppressing gene, Endoglin (ENG), silenced by both epigenetic inactivation and allelic loss in esophageal squamous cell carcinoma. Int J Cancer 2008;123:2816-2823.
23. Kurup S, Abramsson A, Li JP, et al. Heparan sulphate requirement in platelet-derived growth factor Bmediated pericyte recruitment. Biochem Soc Trans 2006;34:454-455.
24. Zweemer RP, Ryan A, Snijders AM, et al. Comparative genomic hybridization of microdissected familial ovarian carcinoma: two deleted regions on chromosome 15q not previously identified in sporadic ovarian carcinoma. Lab Invest 2001;81:1363-1370.
25. Castells A, Gusella JF, Ramesh V, et al. A region of deletion on chromosome 22q13 is common to human breast and colorectal cancers. Cancer Res 2000; 60:2836-2839.
26. Cho YL, Bae S, Koo MS, et al. Array comparative genomic hybridization analysis of uterine leiomyosarcoma. Gynecol Oncol 2005;99:545-551.
27. Dang CV, O'donnell KA, Juopperi T. The great MYC escape in tumorigenesis. Cancer Cell 2005;8:177-178.
28. Conti A, Aguennouz M, La Torre D, et al. miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors. J Neurooncol 2009;93:325-332. [Epub ahead of print].
29. Borkosky SS, Gunduz M, Nagatsuka H, et al. Frequent deletion of ING2 locus at 4q35.1 associates with advanced tumor stage in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol 2008;135:703-713. [Epub ahead of print].
30. Schmidt H, Semjonow A, Csiszar K, et al. Mapping of a deletion interval on 8p21-22 in prostate cancer by gene dosage PCR. Verh Dtsch Ges Pathol 2007;91: 302-307.
31. Perner S, Wagner PL, Soltermann A, et al. TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival. J Pathol 2009;217:65-72.
32. Classon M, Harlow E. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer 2003;2:910-917.
33. Dal Cin P, Boghosian L, Crickard K, et al. t(10;17) as the sole chromosome change in a uterine leiomyosarcoma. Cancer Genet Cytogenet 1988;32:263-266.
34. Packenham JP, du Manoir S, Schrock E, et al. Analysis of genetic alterations in uterine leiomyomas and leiomyosarcomas by comparative genomic hybridization. Mol Carcinog 1997;4:273-279.
35. Leibsohn S, d'Ablaing G, Mishell Jr DR, et al. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol 1990;62:968-974.
36. Osuna D, de Alava E. Molecular pathology of sarcomas. Rev Recent Clin Trials 2009;4:12-26.
37. Woodruff JM. Pathology of tumors of the peripheral nerve sheath in type 1 neurofibromatosis. J Med Genet (Semin Med Genet) 1999;89:23-30.